Cargando…

Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar

BACKGROUND: Artemisinin-based combination therapy (ACT) is a key strategy for global malaria elimination efforts. However, the development of artemisinin-resistant malaria parasites threatens progress and continued usage of oral artemisinin monotherapies (AMT) predisposes the selection of drug resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Thein, Si Thu, Sudhinaraset, May, Khin, Hnin Su Su, McFarland, Willi, Aung, Tin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918101/
https://www.ncbi.nlm.nih.gov/pubmed/27333781
http://dx.doi.org/10.1186/s12936-016-1392-5
_version_ 1782439056965107712
author Thein, Si Thu
Sudhinaraset, May
Khin, Hnin Su Su
McFarland, Willi
Aung, Tin
author_facet Thein, Si Thu
Sudhinaraset, May
Khin, Hnin Su Su
McFarland, Willi
Aung, Tin
author_sort Thein, Si Thu
collection PubMed
description BACKGROUND: Artemisinin-based combination therapy (ACT) is a key strategy for global malaria elimination efforts. However, the development of artemisinin-resistant malaria parasites threatens progress and continued usage of oral artemisinin monotherapies (AMT) predisposes the selection of drug resistant strains. This is particularly a problem along the Myanmar/Thailand border. The artemisinin monotherapy replacement programme (AMTR) was established in 2012 to remove oral AMT from stocks in Myanmar, specifically by replacing oral AMT with quality-assured ACT and conducting behavioural change communication activities to the outlets dispensing anti-malarial medications. This study attempts to quantify the characteristics of outlet providers who continue to stock oral AMT despite these concerted efforts. METHODS: A cross-sectional survey of all types of private sector outlets that were stocking anti-malarial drugs in 13 townships of Eastern Myanmar was implemented from July to August 2014. A total of 573 outlets were included. Bivariate and multivariable logistic regressions were conducted to assess outlet and provider-level characteristics associated with stocking oral AMT. RESULTS: In total, 2939 outlets in Eastern Myanmar were screened for presence of any anti-malarial drugs in August 2014. The study found that 573 (19.5 %) had some kind of oral anti-malarial drug in stock at the time of survey and among them, 96 (16.8 %) stocked oral AMT. In bivariate analyses, compared to health care facilities, itinerant drug vendors, retailers and health workers were less likely to stock oral AMT (33.3 vs 12.9, 10.0, 8.1 %, OR = 0.30, 0.22, 0.18, respectively). Providers who cut blister pack or sell partial courses (40.6 vs 11.7 %, OR 5.18, CI 3.18–8.44) and those who based their stock decision on consumer demand (32.8 vs 12.1 %, OR 3.54, CI 2.21–5.63) were more likely to stock oAMT. Multivariate logistic regressions produced similar significant associations. CONCLUSION: Private healthcare facilities and drug shops and providers who prioritize consumers’ demand instead of recommended practices were more likely to stock oral AMT. Malaria elimination strategies should include targeted interventions to effectively reach those outlets.
format Online
Article
Text
id pubmed-4918101
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49181012016-06-24 Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar Thein, Si Thu Sudhinaraset, May Khin, Hnin Su Su McFarland, Willi Aung, Tin Malar J Research BACKGROUND: Artemisinin-based combination therapy (ACT) is a key strategy for global malaria elimination efforts. However, the development of artemisinin-resistant malaria parasites threatens progress and continued usage of oral artemisinin monotherapies (AMT) predisposes the selection of drug resistant strains. This is particularly a problem along the Myanmar/Thailand border. The artemisinin monotherapy replacement programme (AMTR) was established in 2012 to remove oral AMT from stocks in Myanmar, specifically by replacing oral AMT with quality-assured ACT and conducting behavioural change communication activities to the outlets dispensing anti-malarial medications. This study attempts to quantify the characteristics of outlet providers who continue to stock oral AMT despite these concerted efforts. METHODS: A cross-sectional survey of all types of private sector outlets that were stocking anti-malarial drugs in 13 townships of Eastern Myanmar was implemented from July to August 2014. A total of 573 outlets were included. Bivariate and multivariable logistic regressions were conducted to assess outlet and provider-level characteristics associated with stocking oral AMT. RESULTS: In total, 2939 outlets in Eastern Myanmar were screened for presence of any anti-malarial drugs in August 2014. The study found that 573 (19.5 %) had some kind of oral anti-malarial drug in stock at the time of survey and among them, 96 (16.8 %) stocked oral AMT. In bivariate analyses, compared to health care facilities, itinerant drug vendors, retailers and health workers were less likely to stock oral AMT (33.3 vs 12.9, 10.0, 8.1 %, OR = 0.30, 0.22, 0.18, respectively). Providers who cut blister pack or sell partial courses (40.6 vs 11.7 %, OR 5.18, CI 3.18–8.44) and those who based their stock decision on consumer demand (32.8 vs 12.1 %, OR 3.54, CI 2.21–5.63) were more likely to stock oAMT. Multivariate logistic regressions produced similar significant associations. CONCLUSION: Private healthcare facilities and drug shops and providers who prioritize consumers’ demand instead of recommended practices were more likely to stock oral AMT. Malaria elimination strategies should include targeted interventions to effectively reach those outlets. BioMed Central 2016-06-22 /pmc/articles/PMC4918101/ /pubmed/27333781 http://dx.doi.org/10.1186/s12936-016-1392-5 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Thein, Si Thu
Sudhinaraset, May
Khin, Hnin Su Su
McFarland, Willi
Aung, Tin
Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar
title Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar
title_full Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar
title_fullStr Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar
title_full_unstemmed Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar
title_short Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar
title_sort who continues to stock oral artemisinin monotherapy? results of a provider survey in myanmar
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918101/
https://www.ncbi.nlm.nih.gov/pubmed/27333781
http://dx.doi.org/10.1186/s12936-016-1392-5
work_keys_str_mv AT theinsithu whocontinuestostockoralartemisininmonotherapyresultsofaprovidersurveyinmyanmar
AT sudhinarasetmay whocontinuestostockoralartemisininmonotherapyresultsofaprovidersurveyinmyanmar
AT khinhninsusu whocontinuestostockoralartemisininmonotherapyresultsofaprovidersurveyinmyanmar
AT mcfarlandwilli whocontinuestostockoralartemisininmonotherapyresultsofaprovidersurveyinmyanmar
AT aungtin whocontinuestostockoralartemisininmonotherapyresultsofaprovidersurveyinmyanmar